Rheumatology IV Enrollment Form



 Fax Referral To: 1-855-297-1270
 Phone: 1-888-280-1190

 Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927
 NCPDP: 4026325

Six Simple Steps to Submitting a Referral

PATIENT	INFORMATION (Co	omplete or include demographic sheet)	0	
		DC	B:	Gender: 🗌 Male 🔲 Female
Preferred Cont	tact Methods: 🗌 Phone	(to primary # provided below) Text (to	cell # provided	below) 🗌 Email (to email provided below)
Note: Carrier c	harges may apply. By pro	oviding the phone number(s) and email add	lress above, you	are consenting to receive automated calls,
emails and/or i	text messages from CVS	Specialty® about your prescription(s), acc	ount, and health	care. Standard data rates apply. Message
frequency varie	es. If unable to contact vi	a text or email, Specialty Pharmacy will att	empt to contact	by phone.
		Alternate		
Email:		Last Four of SSN:	Prima	ary Language:
Parent/Caregi	ver/Legal Guardian Nam	ne (Last, First):Relation	nship to patien	ıt:
	BER INFORMATIO	N State	License #:	
NPI #:	DEA #:	Group or Hospital:		
Address:		City, State,	ZIP Code:	
Phone:	Fax	Contact Person:	Contact's I	Phone:
	ICE INFORMATIO	Please fax copy of prescription and in:	surance cards v	with this form, if available (front and back)
				, , , , , , , , , , , , , , , , , , ,
	SIS AND CLINICAL	. INFORMATION		

Diagnosis (ICD-10):

- M06.9 Rheumatoid Arthritis, Unspecified
- M45.9 Non-Radiographic Axial Spondylarthritis (nr-axSpA)
- M45.A0 Ankylosing Spondylitis of Unspecified Sites in Spine
- L40.50 Arthropathic Psoriasis, Unspecified
- L40.59 Other Psoriatic Arthropathy
- M08.00 Unspecified Juvenile Rheumatoid Arthritis of Unspecified Site
- Other Code: _____ Description _____

Patient Clinical Information:

Allerg	ies:
•	

Prior therapy, treatment dates, and reason(s) for discontinuation:

Treatment status: New to therapy Continuation of therapy; date of last treatment ___/__/ Needs by date:

 Weight:
 In/cm
 TB Test Result:
 Date:

Nursing and Administration:

First dose administration of monoclonal antibodies (mABs) should be administered in a controlled setting (may vary depending upon medication specific policy).

For Remicade/Remicade Biosimilars, the first dose must be administered in a controlled setting.

Specialty pharmacy to coordinate home health Infusion nurse visit as necessary? Yes No Site of Care: Home Infusion* Coram Ambulatory Infusion Suite (AIS)* Prescriber's Office** Other Infusion Clinic *Home Infusion/Coram AIS: Diluents, Flushes, Supplies, Nursing Services for drug administration/therapy teach train.

**Prescriber's Office/Other Infusion Clinic: Drug only for facility administration

Rheumatology IV Enrollment Form Medications A-I

		(Actemra, Avsola, Inflectra, Infliximab)	
		plete Patient , Prescriber and Patient Clinical Information	
		Patient DOB: Patient Phone:	
		Prescriber Phone:	
Patient Clinical In			
Allergies:		nt:In/cmTB Test Result:	
Weight:	lb/kg Heigh	nt:In/cm IB Test Result:	Date:
	ON INFORMATIO		
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Actemra	☐ 80 mg/4 mL ☐ 200 mg/10 mL ☐ 400 mg/20 mL	Induction Dose: Infuse 4 mg/kg every 4 weeks. Maintenance Dose: Infuse 8 mg/kg every 4 weeks. Other:	Quantity: Refills:
🗌 Avsola	100 mg vial	 Ankylosing Spondylitis <u>Induction Dose</u>: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis <u>Maintenance Dose</u>: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis <u>Induction Dose</u>: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis <u>Maintenance Dose</u>: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis <u>Induction Dose</u>: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis <u>Maintenance Dose</u>: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis <u>Maintenance Dose</u>: Infuse IV at 3 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other: 	Quantity: # of 100 mg vial(s) Refills:
		Loading Dose: Infuse 6 mg/kg IV (Dose = mg) at Week 0	Quantity: Refill: <u>0</u>
Cosentyx	125 mg/5 mL vial	Maintenance Dose: Infuse 1.75 mg/kg IV (Dose = mg) every 4 weeks (max. maintenance dose 300 mg per infusion) Other:	Quantity: Refill:
 Inflectra Infliximab 	100 mg vial	 Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other: 	Quantity: # of 100 mg vial(s) Refills:
Patient is interested in a	patient support programs	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits prov	rided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do DAW / May Not Substitute	> Not Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	
Prescriber's Signature:	Date:	Prescriber's Signature:	Date:
CA, MA, NC & PR: Interchange is mandated unless Prescril	per writes the words " No Substitution "	ATTN: New York and Iowa provide	ers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Rheumatology IV Enrollment Form Medications J-Z

(Orencia, Remicade, Renflexis, Riabni, Rituxan, Ruxience, Simponi ARIA, Truxima)

			and Patient Clinical Information	
Patient Name:			Patient Phone:	
	e:		rescriber Phone:	
Patient Clinical	Information:			
Allergies:			3 Test Result:	
Weight:	lb/kg Height:	In/cm TE	B Test Result:	Date:
	TION INFORMATION			
MEDICATION	STRENGTH	DOS	E & DIRECTIONS	QUANTITY/REFILLS
🗌 Orencia	250 mg vial	Infuse mg at weeks 0 thereafter. Other:	, 2 and 4, then every 4 weeks	Quantity: Refills:
Remicade Renflexis	100 mg vial	(Dose =mg) at wee Ankylosing Spondylitis M mg/kg (Dose =mg) every 6 Psoriatic Arthritis Inducti (Dose =mg) at wee Psoriatic Arthritis Mainte (Dose =mg) every 8 Rheumatoid Arthritis Ind (Dose =mg) at wee	ion Dose: Infuse IV at 5 mg/kg ks 0, 2, 6 and every 8 weeks thereafter mance Dose: Infuse IV at 5 mg/kg 3 weeks uction Dose: Infuse IV at 3 mg/kg ks 0, 2, 6 and every 8 weeks thereafter intenance Dose: Infuse IV at 3-10 4, 6 or 8 weeks (circle one)	Quantity: # of 100 mg vial(s) Refills:
Riabni	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial	Infuse two doses of 1000 Other:		Quantity: Refills:
Simponi ARIA	50 mg/4 mL in a single use vial	 Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Infuse 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter. Pediatric patients with polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter Other: 		Quantity: # of 50 mg vial Refills:
🗌 Truxima	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial	Other:) mg separated by 2 weeks	Quantity: Refills:
Patient is interested	in patient support programs PRESCRIBER SIG	STAMP SIGNATURE NOT AL	Ancillary supplies and kits provi AMP SIGNATURE NOT ALLOW	ded as needed for administration
DAW / May Not Sub Prescriber's Si	ignature:	o Not Substitute / No Substitution /Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Rheumatology IV Enrollment Form Nursing Orders

	Please Comp	lete Patient , Prescriber and Patient Clinical Information	
Patient Name:		Patient DOB: Patient Phone: _	
Prescriber Name:		Prescriber Phone:	
Patient Clinical Informat			
Allergies:			
Weight:	lb/kg Height:	In/cm TB Test Result:	Date:
		ITEMS BELOW THIS LINE WILL ONLY BE SENT FOR INFUSIONS DONE	AT HOME/CORAM AIS
MEDICATION/SUPPLIES	ROUTE	DOSE /STRENGTH/ DIRECTIONS	QUANTITY/REFILLS
Catheter:	IV	Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV: NS 5 mL (Heparin 10 units/mL 3-5 mL if multiple days) CVC/PICC: NS 10 mL & Heparin 10 units/mL or 100 units/mL 3-5 mL. PORT: 10 mL sterile saline to access PORT w/ huber needle NS 10 mL & Heparin 100 units/mL 3-5mL.	Quantity: Refills:
Hydration:	IV	Pre: 500 mL 1000 mL Other: Concurrent: 500 mL 1000 mL Other: Post: 500 mL 1000 mL Other:	Hydration max infusion rate mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)
Epinephrine **nursing requires**	□ IM □ sc	 1:1000, 0.3mg/0.3 mL (greater than 30 kg/66 lbs) 1:2000, 0.15mg/0.3 mL (15-30 kg/33-66 lbs) 1:1000, 0.1 mg/kg, Max 0.3mg (under 15kg) Mild-Moderate Reactions. May repeat in 3-5 minutes as needed for severe allergic reaction, also call 911 	Quantity: Refills:
Diphenhydramine Oral	PO	Premedication: 12.5 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg)	Quantity: Refills:
Diphenhydramine 50 mg/mL vial **nursing required**	Slow IV	 1 mg/kg (under 15 kg) 12.5 mg-50 mg (15-30 kg) 25 mg-50 mg (Over 30 kg) If mild/moderate reaction: may repeat in 3-5 minutes as needed (Adult max dose: 100 mg/day) If severe allergic reaction: call 911 	Quantity: Refills:
Flush Orders:	 Peripheral Access Central Venous Access 	 10 mL NS post flush 50 mL NS post flush to clear medication from tubing (recommended if no post-hydration) Other: 	Send quantity sufficient for medication days supply
Additional Medication:			
Patient is interested in patient supp	port programs	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits	provided as needed for administrati

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

DAW / May Not Substitute Prescriber's Signature:Date:	Substitution Permissible Prescriber's Signature:Date:
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution"	ATTN: New York and Iowa providers, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Speciality and/or one of its affiliates.